샘플 요청 목록

 카트 문의
시장보고서
상품코드
1779772

세계의 콜레라 백신 시장

Cholera Vaccines
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 367 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 콜레라 백신 시장은 2030년까지 1억 4,740만 달러에 달할 전망

2024년에 9,110만 달러로 추정되는 세계의 콜레라 백신 시장은 2030년에는 1억 4,740만 달러에 달하며, 분석 기간인 2024-2030년의 CAGR은 8.4%로 성장할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 Killed Oral O1 및 O139 백신은 CAGR 10.1%를 기록하며, 분석 기간 종료까지 8,640만 달러에 달할 것으로 예측됩니다. Whole Cell v. Cholerae O1 with Recombinant B-Subunit Vaccine 부문의 성장률은 분석 기간 중 CAGR 6.2%로 추정됩니다.

미국 시장은 2,480만 달러로 추정되는 한편, 중국은 CAGR 13.3%로 성장할 것으로 예측

미국의 콜레라 백신 시장은 2024년에는 2,480만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년의 CAGR 13.3%로 추이하며, 2030년에는 예측 시장 규모 3,240만 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 4.1%와 8.1%로 예측됩니다. 유럽에서는 독일이 CAGR 5.6%로 성장할 것으로 예측됩니다.

세계의 콜레라 백신 시장 - 주요 동향과 촉진요인 정리

콜레라 백신에 대한 수요가 증가하는 이유는 무엇인가?

콜레라 백신 수요 증가는 콜레라 발생 증가, 유행 지역에서의 예방 의료 대책의 필요성 증가, 공중 보건 위협으로서의 콜레라 퇴치를 위한 전 세계적인 노력의 배경에 기인합니다. 콜레라는 개발도상국, 특히 위생 환경이 열악하고 깨끗한 물에 대한 접근이 제한적인 지역에서 여전히 큰 우려를 낳고 있습니다. 도시화와 기후 변화가 수인성 전염병의 확산을 부추기는 가운데, 콜레라 감염을 예방할 수 있는 효과적인 백신에 대한 수요가 증가하고 있습니다. 정부, 비정부기구, 세계보건기구(WHO), 백신동맹(Gavi) 등 국제보건기구는 대규모 콜레라 예방접종 프로그램에 적극적으로 투자하고 있습니다. 집단 예방접종, 백신 긴급 비축, 백신 개발을 위한 자금 증가 등이 시장 개발에 더욱 박차를 가하고 있습니다. 또한 고위험 지역으로의 여행이 증가함에 따라 여행자들 사이에서 콜레라 백신의 채택이 증가하고 있으며, 이는 수요를 더욱 증가시키고 있습니다. 세계 보건에 대한 노력이 계속 확대되고 있는 가운데, 콜레라 백신에 대한 수요는 계속 증가하고 있습니다.

기술의 발전은 어떻게 콜레라 백신을 개선하고 있는가?

백신 개발, 생산 효율성, 전달 메커니즘의 발전은 콜레라 백신의 접근성과 효능을 크게 향상시켰습니다. 가장 주목할 만한 기술 혁신 중 하나는 경구용 콜레라 백신의 개발로, 대량 예방접종 캠페인에서 보다 간편한 투약과 광범위한 적용 범위를 실현하고 있습니다. 사독화 전세포 백신이나 약독화 생백신과 같은 이러한 백신은 주사 백신과 관련된 물류 문제를 줄이면서 장기적인 면역력을 제공합니다. 또 다른 큰 도약은 백신 제조에 있으며, 재조합 DNA 기술과 합성생물학의 도입입니다. 이러한 혁신을 통해 보다 안정적이고 저렴하며 확장 가능한 백신을 생산할 수 있게 되었으며, 콜레라가 가장 많이 발생하는 저소득 지역에서도 백신을 사용할 수 있게 되었습니다. 또한 콜드체인 물류와 열 안정성 제제의 개선으로 인프라가 제한된 원격지에서도 더 나은 백신 배포가 가능해졌습니다. 백신 기술이 계속 발전함에 따라 전 세계에서 콜레라 예방접종 프로그램의 범위가 확대되어 취약 계층의 질병 부담을 줄일 수 있을 것으로 기대됩니다.

콜레라 백신 시장의 성장을 주도하는 시장 동향은?

예방 의료와 전염병 대책에 대한 관심이 높아지는 것은 콜레라 백신 시장을 형성하는 주요 동향 중 하나입니다. 정부와 국제기구는 유행 후 치료에만 의존하는 것이 아니라, 유행병을 예방하기 위한 적극적인 백신 접종 캠페인을 우선시하고 있습니다. 이러한 접근 방식의 변화로 인해 비축 백신에 대한 수요가 증가하고 있으며, 고위험 지역에서는 선제적 예방접종에 대한 노력이 이루어지고 있습니다. 시장 성장에 영향을 미치는 또 다른 중요한 추세는 백신 연구 및 유통에 있으며, 민관 파트너십의 확대입니다. 제약사, 연구기관, 국제보건기구가 협력하여 콜레라 백신 개발의 혁신을 촉진하고, 의료 서비스를 받지 못하는 지역의 백신 접근성을 개선하고 있습니다. 또한 콜레라를 포함한 여러 세균 감염을 예방하는 혼합 백신의 등장은 비용 효율적이고 효율적인 예방접종 전략으로 주목받고 있습니다. 이러한 추세에 따라 콜레라 백신은 전 세계 공중보건 활동의 핵심적인 툴로 자리 잡고 있습니다.

콜레라 백신 시장의 미래를 좌우할 주요 성장 동력은 무엇인가?

콜레라 백신 시장의 성장은 예방접종 프로그램에 대한 투자 증가, 콜레라 예방에 대한 인식 증가, 백신 제조 기술의 발전 등 여러 가지 요인에 기인합니다. 주요 성장 요인 중 하나는 콜레라가 유행하는 지역을 대상으로 한 인도적 및 긴급 대응 구상 증가입니다. 재해 구호 및 난민 보건 프로그램에 종사하는 단체들은 콜레라 예방접종을 표준 예방책으로 채택하고 있으며, 이는 수요를 더욱 증가시키고 있습니다. 시장을 형성하는 또 다른 중요한 요인은 여행 관련 백신 권장 사항의 확대입니다. 업무, 관광, 인도주의적 임무를 위해 콜레라 발생 지역을 방문하는 사람들이 늘어남에 따라 여행 전 예방접종에 대한 수요가 증가하고 있습니다. 또한 효능이 개선되고 면역력이 더 오래 지속되는 차세대 백신에 대한 연구가 진행되고 있으며, 더욱 확산될 것으로 기대됩니다. 콜레라 퇴치를 위한 전 세계적인 노력이 계속되는 가운데, 백신 시장은 지속적인 성장세를 보이며 유행 지역과 고위험 지역 모두에서 건강 성과가 개선될 것으로 예측됩니다.

부문

제품 유형(Killed Oral O1 및 O139 백신, 전세포 v. 콜레라균 O1과 재조합 B 서브유닛 백신); 콜레라균 유형(Dukoral, Vaxchora, Shanchol, 기타); 유통 채널(병원 약국, 소매 약국, 기타 유통 채널)

조사 대상 기업의 예

  • Astellas Pharma Inc.
  • Bavarian Nordic
  • Bharat Biotech Ltd.
  • Celldex Therapeutics
  • Emergent BioSolutions Inc.
  • EuBiologics Co., Ltd.
  • GlaxoSmithKline plc(GSK)
  • Hilleman Laboratories
  • Incepta Vaccine Ltd.
  • International Vaccine Institute
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • PaxVax, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Shanghai United Cell Biotechnology Co., Ltd.
  • Shantha Biotechnics Limited
  • Takeda Pharmaceutical Company Limited
  • Vabiotech
  • Valneva SE

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계 고유 SLM를 쿼리 하는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.06

Global Cholera Vaccines Market to Reach US$147.4 Million by 2030

The global market for Cholera Vaccines estimated at US$91.1 Million in the year 2024, is expected to reach US$147.4 Million by 2030, growing at a CAGR of 8.4% over the analysis period 2024-2030. Killed Oral O1 and O139 Vaccine, one of the segments analyzed in the report, is expected to record a 10.1% CAGR and reach US$86.4 Million by the end of the analysis period. Growth in the Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$24.8 Million While China is Forecast to Grow at 13.3% CAGR

The Cholera Vaccines market in the U.S. is estimated at US$24.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$32.4 Million by the year 2030 trailing a CAGR of 13.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Global Cholera Vaccines Market - Key Trends & Drivers Summarized

Why Is the Demand for Cholera Vaccines Increasing?

The demand for cholera vaccines is increasing due to the rising incidence of cholera outbreaks, the growing need for preventive healthcare measures in endemic regions, and global initiatives aimed at eliminating cholera as a public health threat. Cholera remains a major concern in developing countries, particularly in areas with inadequate sanitation and limited access to clean water. As urbanization and climate change contribute to the spread of waterborne diseases, the demand for effective vaccines to prevent cholera infections has intensified. Governments, non-governmental organizations, and global health agencies such as the World Health Organization and Gavi, the Vaccine Alliance, are actively investing in large-scale cholera vaccination programs. Mass immunization efforts, emergency stockpiling of vaccines, and increased funding for vaccine development have further driven market growth. Additionally, rising travel to high-risk areas has led to an increase in the adoption of cholera vaccines among travelers, further boosting demand. As global health initiatives continue to expand, the need for cholera vaccines remains strong.

How Are Technological Advancements Improving Cholera Vaccines?

Advancements in vaccine development, production efficiency, and delivery mechanisms are significantly improving the accessibility and effectiveness of cholera vaccines. One of the most notable innovations is the development of oral cholera vaccines, which provide easier administration and broader coverage in mass immunization campaigns. These vaccines, such as those using killed whole-cell or live-attenuated strains, offer long-lasting immunity while reducing logistical challenges associated with injectable vaccines. Another major breakthrough is the implementation of recombinant DNA technology and synthetic biology in vaccine manufacturing. These innovations allow for the production of more stable, affordable, and scalable vaccines, making them accessible to low-income regions where cholera is most prevalent. Additionally, improvements in cold chain logistics and heat-stable formulations are enabling better vaccine distribution in remote areas with limited infrastructure. As vaccine technology continues to evolve, the global reach of cholera immunization programs is expected to expand, reducing the disease burden in vulnerable populations.

Which Market Trends Are Driving Growth in the Cholera Vaccines Market?

The increasing focus on preventive healthcare and epidemic preparedness is one of the key trends shaping the cholera vaccines market. Governments and international organizations are prioritizing proactive vaccination campaigns to prevent outbreaks rather than relying solely on post-epidemic treatment. This shift in approach has led to greater demand for stockpiled vaccines and preemptive immunization efforts in high-risk regions. Another significant trend influencing market growth is the expansion of public-private partnerships in vaccine research and distribution. Collaborations between pharmaceutical companies, research institutions, and global health organizations are driving innovations in cholera vaccine development and improving access to vaccines in underserved areas. Additionally, the rise of combination vaccines that protect against multiple bacterial infections, including cholera, is gaining attention as a cost-effective and efficient immunization strategy. As these trends continue to shape the market, cholera vaccines are becoming a central tool in global public health efforts.

What Are the Key Growth Drivers Shaping the Future of the Cholera Vaccines Market?

The growth of the cholera vaccines market is driven by several factors, including increasing investments in immunization programs, rising awareness of cholera prevention, and advancements in vaccine production technology. One of the primary growth drivers is the growing number of humanitarian and emergency response initiatives targeting cholera-endemic regions. Organizations involved in disaster relief and refugee health programs are incorporating cholera vaccination as a standard preventive measure, further driving demand. Another crucial factor shaping the market is the expansion of travel-related vaccine recommendations. As more people travel to cholera-prone areas for work, tourism, or humanitarian missions, the demand for pre-travel vaccination has increased. Additionally, ongoing research into next-generation cholera vaccines with improved efficacy and longer-lasting immunity is expected to drive further adoption. With continued global efforts to control and eliminate cholera, the market for vaccines is set to experience sustained growth, improving health outcomes in both endemic and high-risk regions.

SCOPE OF STUDY:

The report analyzes the Cholera Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Killed Oral O1 and O139 Vaccine, Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine); Cholera Type (Dukoral, Vaxchora, Shanchol, Other Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Astellas Pharma Inc.
  • Bavarian Nordic
  • Bharat Biotech Ltd.
  • Celldex Therapeutics
  • Emergent BioSolutions Inc.
  • EuBiologics Co., Ltd.
  • GlaxoSmithKline plc (GSK)
  • Hilleman Laboratories
  • Incepta Vaccine Ltd.
  • International Vaccine Institute
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • PaxVax, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Shanghai United Cell Biotechnology Co., Ltd.
  • Shantha Biotechnics Limited
  • Takeda Pharmaceutical Company Limited
  • Vabiotech
  • Valneva SE

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Cholera Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Cholera Outbreaks Throws the Spotlight on Vaccine Deployment and Access
    • Growing Emphasis on Public Health Preparedness Expands Addressable Market for Cholera Immunization Programs
    • Increased Demand in Endemic and Humanitarian Crisis Regions Drives Accelerated Vaccine Distribution Efforts
    • Advancements in Oral Cholera Vaccine (OCV) Formulations Propel Market Growth Through Improved Compliance
    • Global Health Initiatives and WHO Endorsements Strengthen the Business Case for Mass Vaccination Campaigns
    • Surge in International Funding and Gavi Support Fuels Vaccine Procurement and Cold Chain Infrastructure Development
    • Government-Driven Immunization Programs in Low-Income Countries Generate High-Volume Demand for Cost-Effective Vaccines
    • Technological Innovations in Vaccine Manufacturing and Storage Enhance Product Stability and Scalability
    • Integration of Cholera Vaccines into Routine Immunization Schedules Drives Sustainable Demand in High-Risk Regions
    • Urbanization, Climate Change, and Water Contamination Trends Increase Vulnerability and Drive Vaccine Adoption
    • Rising Traveler Awareness and Pre-Travel Vaccination Requirements Fuel Demand in Non-Endemic Markets
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cholera Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cholera Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cholera Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Cholera Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Killed Oral O1 and O139 Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Killed Oral O1 and O139 Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Killed Oral O1 and O139 Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Dukoral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Dukoral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Dukoral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Vaxchora by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Vaxchora by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Vaxchora by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Shanchol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Shanchol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Shanchol by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Cholera Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Cholera Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Cholera Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Cholera Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Cholera Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Cholera Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Cholera Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Cholera Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Cholera Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Cholera Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Cholera Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Cholera Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제